Outdated Product Labeling and Implications for Contemporary Standards of Care: The Example of Clozapine
- 22 October 2026
- journal article
- Published by American Psychiatric Association Publishing in Psychiatric Services
Abstract
Discontinuation of the U.S. Food and Drug Administration's clozapine risk evaluation and mitigation strategy program led to a package insert (PI) revision in June 2025. However, that PI update retained many elements that are inconsistent with modern clozapine prescribing, including rapid titration, twice-daily dosing at the start of therapy, and titration without regard to patient factors (e.g., ancestry, sex and gender, or smoking status). The revision also provided no guidance on monitoring for myocarditis or mitigating the primary causes of mortality-pneumonia and ileus. This discrepancy between the clozapine PI and evidence-based practices has caused clinicians to consider whether deviation from the PI presents a medicolegal risk and how to cope with outdated PI information for clozapine and other medications. This article reviews the relative weight of different forms of medical evidence in establishing the standard of care, illustrates through case law that a PI does not define the standard of care and is inadmissible in malpractice litigation without expert testimony, and provides guidance for clinicians on how to navigate outdated, non-evidence-based PI recommendations. The information in this article should reassure clinicians that using modern evidence-based care-not archaic PI recommendations-is the optimal choice when treating patients.Keywords
This publication has 41 references indexed in Scilit:
- Underprescription of Clozapine: A Narrative Review Regarding ‘Clozaphobia’Human Psychopharmacology: Clinical and Experimental, 2026
- Predictors of early discontinuation of clozapine under rapid titration in a Turkish tertiary inpatient settingSchizophrenia Research, 2026
- Updating clozapine prescribing guidelines in Italy: a step forward modernityEuropean Neuropsychopharmacology, 2026
- FDA Eliminates the Clozapine REMS—What Comes Next?JAMA Psychiatry, 2025
- A New Legal Standard for Medical MalpracticeJAMA, 2025
- Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in SingaporeSchizophrenia Research, 2023
- Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospitalSchizophrenia Research, 2023
- A 12-month audit of clozapine associated myocarditis in a South Australian Local Health Network: The importance of screening and personalised titrationSchizophrenia Research, 2023
- Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: A retrospective chart review of seven hospitalsSchizophrenia Research, 2023
- Japanese patients need slower, personalized clozapine titrations: A comment on the case described by Kikuchi et al.Psychiatry and Clinical Neurosciences Reports, 2023